Medicilon offers fully integrated pharmaceutical services for the global scientific community and is focused on providing an exceptional client-centered experience and advancing the drug discovery process.
Preclinical Services
Medicilon’s Preclinical department has extensive and professional knowledge in drug metabolism/pharmacokinetics, pharmacology studies as well as toxicology. We offer high-quality and cost-effective data with rapid turnaround time to support drug development, preclinical studies and clinical research. Our services cover various aspects of preclinical services, including protocol designing, in-life studies, sample analysis, professional data analysis, IACUC review, and preparation of documents for IND filing.Biology Services
Medicilon’s Biology department has extensive research experience in the fields of molecular biology, cell biology, structural biology and in vitro biology. From initial construction of cDNA library to drug design as well as from protein purification to structural determination and assays, we provide a complete set of biological services.Chemistry Services
Medicilon’s Chemistry department provides custom synthesis, medicinal chemistry, focus library preparation, and process and scale-up synthesis. Either in FTE or integrated project team arrangement, our medicinal chemistry group has helped clients discover novel, potent, and highly druggable chemical series. Our contribution has led to several pre-clinical and clinical candidates. We also provide scale up service to deliver kilogram of material with high-quality and on-time delivery.CMC Services
We have the professional formulation technical platform and the most experienced elite team, which could offer fully integrated pharmaceutical services and meet different requirements of our clients. We focus on the development of solid dosage forms, semisolid dosage forms, liquid dosage forms and sterile dosage forms. Our formulation group is also highly experienced in developing sustained release dosage forms, micro-particle dosage forms, protein and peptide drugs, etc. We have a good track record of successful integrated drug development programs for our clients.
Global pharma sales are predicted to grow to $1.3 trillion by 2018
回复删除URL：http://www.medicilon.com/ china CRO
Email:marketin@medicilon.com.cn
Tel:86-021-58591500
Global pharma sales are predicted to grow to $1.3 trillion by 2018, according to a new report.
Worldwide sales passed the $1 trillion mark for the first time in 2014, and the 2015 CMR Pharmaceutical R&D Factbook from Thomson Reuters predicts that this increase will continue coupled with a rise in R&D productivity.
The authors note that 2014 saw the highest number of first-world new molecular entity (NME) launches in over a decade, with 46 such drugs entering the market. They say that this goes against perceptions that the industry is in a “era of scarcity”.
One third of these drugs were for rare indications, and more than 65% were speciality drugs for the treatment of cancer, hepatitis C and HIV.
Cancer in particular continues to attract the highest amount of investments across all therapeutic areas, with the majority of recent launches receiving orphan drug status from regulators
Pharma companies are also improving their ability to “fail fast and cheaply” and process drugs that are more likely to succeed in later phases, leading to steady growth in Phase III pipeline volumes.
“This is an extraordinary year for pharma,” said Basil Moftah, president of Thomson Reuters IP & Science. “Not only do the critical insights provided by the Factbook challenge negative perceptions, but it demonstrates this industry’s continued commitment to creating and employing innovative solutions to tackle its largest hurdles.”